WebFeb 4, 2024 · Feb 4, 2024 Larry Hanover A new study of dupilumab indicates that the drug is a safe and effective treatment for atopic dermatitis (AD) in elderly patients, with efficacy comparable to that seen... WebMay 17, 2024 · Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma in a randomized Phase …
Dupilumab Is Safe, Effective Among Elderly Patients With AD
WebFeb 22, 2024 · The safety profile of dupilumab in TRAVERSE was consistent with the safety profile observed in pivotal asthma studies for up to 52 weeks of treatment. In children 6 to 11 years of age with moderate-to-severe asthma (VOYAGE), the additional adverse reaction of enterobiasis was reported in 1.8 % (5 patients) in the dupilumab groups and … WebAbstract. Sanofi and Regeneron's Dupixent (dupilumab)-which is already approved for atopic dermatitis-has an FDA action date of October 20 for its asthma indication. It will … dylan scott facebook
Pivotal data at ATS 2024 show Dupixent - Sanofi
WebMar 23, 2024 · Dupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), see section 5.1, who are inadequately controlled with high dose inhaled corticosteroids (ICS) plus … WebMay 26, 2024 · Data from Dupixent clinical trials have shown that IL-4 and IL-13 are key drivers of the type 2 inflammation that plays a major role in atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP). Across all approved indications globally, more than 150,000 patients have been treated with Dupixent. WebMay 7, 2024 · For this condition, Dupixent is used as an add-on treatment to help prevent asthma symptoms in adults and some children. As an add-on treatment, it’s used … dylan scott concert 2021